Acceptance of the CP950 Sound Processor
Launched by COCHLEAR · Aug 2, 2018
Trial Information
Current as of April 27, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Eighteen years of age or older
- • 2. At least 6 months experience with a Nucleus 24 series or later implant in at least one implanted ear
- • 3. At least 3 months experience with the CP810,CP920 or CP910 sound processor
- • 4. Native speaker in the language used to assess speech perception performance
- • 5. Willingness to participate in and to comply with all requirements of the protocol
- • 6. Able to score 30% or more at +15 SNR with CI alone
- Exclusion Criteria:
- • 1. Unrealistic expectations on the part of the subject, regarding the possible benefits, risks and limitations that are inherent to the procedure and prosthetic device
- • 2. Additional disabilities that would prevent participation in evaluations
- • 3. Nucleus 22 Implant
About Cochlear
Cochlear Limited is a global leader in implantable hearing solutions, dedicated to transforming the lives of individuals with hearing loss through innovative technology and comprehensive clinical research. With a strong commitment to advancing auditory rehabilitation, Cochlear conducts rigorous clinical trials aimed at evaluating the safety and efficacy of its products, including cochlear implants and bone conduction devices. The company collaborates with healthcare professionals and research institutions worldwide to ensure that its solutions meet the highest standards of quality and performance, ultimately enhancing patient outcomes and promoting accessibility to hearing health care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials